title: Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial.
abstract: BACKGROUND
  To determine the prevalence of visual field (VF) performance failures (PF) and treatment failures (TFs), and identify factors associated with PFs in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
  
  
  METHODS
  A total of 165 participants from 38 sites with idiopathic intracranial hypertension (IIH) and mild visual loss were randomized to either acetazolamide-plus diet or placebo-plus diet. The IIHTT Visual Field Reading Center evaluated 2950 Swedish Interactive Threshold Algorithm Standard 24-2 VFs from the enrolled participants. A TF was defined when the participant's VF mean deviation (MD) worsened ≥2 to 3 dB from the average baseline MD (range of -2 to -7 dB) with a second retest confirming the visual deterioration. A PF was determined when the participant's: 1) VF results met TF criteria but were not confirmed on retest, 2) deterioration was confirmed on retest but the IIHTT Adjudication Committee concluded a TF was clinically unlikely.
  
  
  RESULTS
  TF was detected in 7/165 (4%) of the participants and PF was detected in 35/165 (21%) of the participants on at least 1 examination. Four of the 35 PFs were adjudicated for TF, however based on clinical review by the adjudication committee and a third retest, they were judged as PFs. Of the 2,950 total IIHTT VF examinations, 2.7% met PF criteria.
  
  
  CONCLUSIONS
  PF was confirmed in 21% of subjects and in 2.7% of the total number of VF examinations and was reversible on repeat testing. We recommend retesting when perimetric worsening occurs in otherwise clinically stable or improving IIH patients.
authors.affiliation: Departments of Ophthalmology and Vision Science (KEC), and Neurology and Neurological Surgery (JLK), University of California Davis, California; Department of Ophthalmology and Visual Sciences (CAJ), University of Iowa, Iowa City, Iowa; and Department of Neurology and Ophthalmology (MW), College of Medicine, University of Iowa, Iowa City, Iowa.
authors.forename: Kimberly E
authors.initials: KE
authors.lastname: Cello
authors.forename: John L
authors.initials: JL
authors.lastname: Keltner
authors.forename: Chris A
authors.initials: CA
authors.lastname: Johnson
authors.forename: Michael
authors.initials: M
authors.lastname: Wall
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004039:Diet, Sodium-Restricted; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010211:Papilledema / Q000503:physiopathology; D011559:Pseudotumor Cerebri / Q000178:diet therapy* / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D012307:Risk Factors; D017211:Treatment Failure; D014786:Vision Disorders / Q000503:physiopathology*; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide